Ellume Announces $231.8 Million Agreement with the U.S. Government to Scale Up Production of COVID-19 Home Tests
Formzoo is so incredibly excited, that a team we’re so proud to be a part of, has reached such a momentous milestone.
The contract includes the delivery of 8.5 million Ellume COVID-19 Home Tests to support the U.S. Government’s pandemic response
- The investment will support the establishment of Ellume’s first U.S. manufacturing facility, increasing Ellume’s global production capacity by 500,000+ tests per day once completed;
- The investment extends Ellume’s engagement with the U.S. government following the NIH RADx announcement last year;
- The Ellume COVID-19 Home Test is the first non-prescription over-the-counter self-test authorized by the U.S. Food and Drug Administration
Digital diagnostics company Ellume today announced a $231.8 million agreement with the U.S. Department of Defense (DOD), in coordination with the Department of Health and Human Services (HHS), to accelerate domestic US production of its COVID-19 home tests.
The Ellume COVID-19 Home Test is the first rapid self-test for COVID-19 detection authorized by the U.S. FDA for both asymptomatic and symptomatic use without a prescription. With the CDC reporting that at least 50% of COVID-19 cases are transmitted asymptomatically, Ellume’s test will play a crucial role as the only diagnostic tool authorized for non-prescription use as a screening tool in the United States.
The agreement includes funding to support the establishment of Ellume’s U.S.-based manufacturing facility and the delivery of 8.5 million COVID-19 home tests that will be distributed across the U.S. in accordance with the National Strategy for the COVID-19 Response and Pandemic Preparedness plan.
This US-based manufacturing capacity builds upon Ellume’s existing Australian production capacity which is on-track to procure approximately 200,000 tests per day this quarter. Under the agreement, Ellume will be delivering 100,000 tests per month from the Australian manufacturing facility until the U.S. facility is built. At full capacity, the U.S facility will be able to produce up to 19 million tests per month.
Original Article: Ellume Health